- Home
- EGY vs CRVS Comparison
EGY vs CRVS Comparison
Compare EGY & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGY
- CRVS
- Stock Information
- Founded
- EGY 1985
- CRVS 2014
- Country
- EGY United States
- CRVS United States
- Employees
- EGY N/A
- CRVS N/A
- Industry
- EGY Oil & Gas Production
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- EGY Energy
- CRVS Health Care
- Exchange
- EGY Nasdaq
- CRVS Nasdaq
- Market Cap
- EGY 497.4M
- CRVS 516.0M
- IPO Year
- EGY N/A
- CRVS 2016
- Fundamental
- Price
- EGY $4.69
- CRVS $4.86
- Analyst Decision
- EGY Strong Buy
- CRVS Buy
- Analyst Count
- EGY 1
- CRVS 4
- Target Price
- EGY $8.00
- CRVS $12.83
- AVG Volume (30 Days)
- EGY 1.0M
- CRVS 765.4K
- Earning Date
- EGY 11-11-2024
- CRVS 11-12-2024
- Dividend Yield
- EGY 5.31%
- CRVS N/A
- EPS Growth
- EGY 170.05
- CRVS N/A
- EPS
- EGY 0.86
- CRVS N/A
- Revenue
- EGY $506,421,000.00
- CRVS N/A
- Revenue This Year
- EGY $0.48
- CRVS N/A
- Revenue Next Year
- EGY N/A
- CRVS N/A
- P/E Ratio
- EGY $5.48
- CRVS N/A
- Revenue Growth
- EGY 25.82
- CRVS N/A
- 52 Week Low
- EGY $4.03
- CRVS $1.30
- 52 Week High
- EGY $7.51
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- EGY 32.96
- CRVS 40.84
- Support Level
- EGY $4.74
- CRVS $7.88
- Resistance Level
- EGY $5.08
- CRVS $8.33
- Average True Range (ATR)
- EGY 0.18
- CRVS 0.56
- MACD
- EGY -0.00
- CRVS -0.19
- Stochastic Oscillator
- EGY 21.91
- CRVS 30.55
About EGY VAALCO Energy Inc.
VAALCO Energy Inc is an independent energy company operating in the United States. It is principally engaged in the acquisition, exploration, development, and production of crude oil and natural gas. The company operates through geographical segments namely Gabon, Egypt, Canada, Equatorial Guinea and Corporate and Other. The company generates maximum revenue from the Gabon segment.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).